scholarly journals Experience of effective antiviral therapy in a liver recipient with recurrent HCV infection genotype 1

2019 ◽  
Vol 20 (4) ◽  
pp. 54-60
Author(s):  
D. V. Umrik ◽  
O. M. Tsiroulnikova ◽  
I. A. Miloserdov ◽  
R. A. Latypov ◽  
E. T. Egorova
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Antiviral Therapy ◽  
Liver Diseases ◽  
Hcv Infection ◽  
Rapid Progression ◽  
Genotype 1 ◽  
Wide Range ◽  
Common Causes ◽  
Before And After

HCV infection is one of the most common causes leading to the development of terminal liver diseases – cirrhosis and hepatocellular carcinoma, the main treatment for which is orthotopic liver transplantation. However, with continued virus replication, 100% reinfection occurs, which leads to the rapid progression of cirrhosis of the graft and the loss of its function. Standard interferon-containing therapy is ineffective for HCV infection, especially genotype 1, both before and after transplantation, and also has a wide range of adverse events. The article presents the successful experience of treating the recurrence of HCV infection 1 genotype in a patient who underwent liver transplantation and several courses of ineffective antiviral therapy.

scholarly journals Liver transplantation in a patient with hepatitis B, C and D coinfection associated with hepatocellular carcinoma: a management strategy for a rare condition. Case report

2015 ◽  
Vol 133 (6) ◽  
pp. 525-530 ◽  
Author(s):  
Lucas Carvalho Dantas ◽  
Tércio Genzini ◽  
Marcelo Perosa de Miranda ◽  
Regina Gomes dos Santos ◽  
Nilton Ghiotti de Siqueira ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Case Report ◽  
Hepatitis C ◽  
Hepatitis B ◽  
Antiviral Therapy ◽  
Rare Condition ◽  
Hepatitis C Infection ◽  
Hepatitis D ◽  
Before And After

CONTEXT: Orthotopic liver transplantation (OLT) is the treatment of choice for end-stage liver disease. Cirrhosis due to hepatitis C infection is the leading indication for liver transplantation worldwide. However, patients who are given transplants because of viral liver diseases often present clinical coinfections, including hepatitis B together with hepatitis D. Currently, different strategies exist for patient management before and after liver transplantation, and these are based on different protocols developed by the specialized transplantation centers. CASE REPORT: We present a rare case of a 58-year-old man with chronic hepatitis B, C and D coinfection. The patient developed cirrhosis and hepatocellular carcinoma. His treatment comprised antiviral therapy for the three viruses and OLT. The patient's outcome was satisfactory. CONCLUSION: OLT, in association with antiviral therapy using entecavir, which was administered before and after transplantation, was effective for sustained clearance of the hepatitis B and D viruses. A recurrence of hepatitis C infection after transplantation responded successfully to standard treatment comprising peginterferon alfa-2A and ribavirin.

Bone density and metabolism in patients with viral hepatitis and cholestatic liver diseases before and after liver transplantation

2000 ◽  
Vol 95 (9) ◽  
pp. 2343-2351 ◽  
Author(s):  
Christian Trautwein ◽  
Martin Possienke ◽  
Hans-Jorg Schlitt ◽  
Klaus H.W. Boker ◽  
Roland Horn ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Bone Density ◽  
Viral Hepatitis ◽  
Liver Diseases ◽  
Before And After

scholarly journals Data on Adiponectin from 2010 to 2020: Therapeutic Target and Prognostic Factor for Liver Diseases?

2020 ◽  
Vol 21 (15) ◽  
pp. 5242 ◽  
Author(s):  
Misaq Heydari ◽  
María Eugenia Cornide-Petronio ◽  
Mónica B. Jiménez-Castro ◽  
Carmen Peralta
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Liver Disease ◽  
Therapeutic Target ◽  
Liver Diseases ◽  
Therapeutic Strategies ◽  
Potential Therapeutic Target ◽  
Surgical Interventions ◽  
Scientific Controversies

The review describes the role of adiponectin in liver diseases in the presence and absence of surgery reported in the literature in the last ten years. The most updated therapeutic strategies based on the regulation of adiponectin including pharmacological and surgical interventions and adiponectin knockout rodents, as well as some of the scientific controversies in this field, are described. Whether adiponectin could be a potential therapeutic target for the treatment of liver diseases and patients submitted to hepatic resection or liver transplantation are discussed. Furthermore, preclinical and clinical data on the mechanism of action of adiponectin in different liver diseases (nonalcoholic fatty disease, alcoholic liver disease, nonalcoholic steatohepatitis, liver cirrhosis and hepatocellular carcinoma) in the absence or presence of surgery are evaluated in order to establish potential targets that might be useful for the treatment of liver disease as well as in the practice of liver surgery associated with the hepatic resections of tumors and liver transplantation.

Bone metabolism in chronic liver diseases before and after liver transplantation

1998 ◽  
Vol 28 ◽  
pp. 65
Author(s):  
C. Trautwein ◽  
M. Possienke ◽  
K.H.W. Böker ◽  
R. Horn ◽  
H.-J. Schlitt ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Bone Metabolism ◽  
Liver Diseases ◽  
Chronic Liver ◽  
Chronic Liver Diseases ◽  
Before And After

THE USE OF GROWTH FACTORS CAN IMPROVE RESULTS OF ANTIVIRAL THERAPY IN PTS WITH RECURRENT HCV INFECTION AFTER LIVER TRANSPLANTATION (LTX)

2010 ◽  
Vol 90 ◽  
pp. 855
Author(s):  
M. S. Hubutiya ◽  
V. E. Syutkin ◽  
A. A. Salienko ◽  
O. I. Andreytzeva ◽  
A. V. Chzhao
Keyword(s):  
Liver Transplantation ◽  
Growth Factors ◽  
Antiviral Therapy ◽  
Hcv Infection
Sign in / Sign up

Export Citation Format

Share Document